Early initiation of gonadotropin-releasing hormone (GnRH) antagonist during assisted reproductive technology (ART)

ISRCTN ISRCTN53514546
DOI https://doi.org/10.1186/ISRCTN53514546
Secondary identifying numbers 195632-1
Submission date
03/08/2011
Registration date
26/08/2011
Last edited
14/02/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
In vitro fertilisation (IVF) is an assisted reproductive technology (ART) technique to help people with fertility problems to have a baby. Patients undergoing IVF receive various treatments to stimulate the release of multiple eggs from the ovaries. Sometimes a type of medication called gonadotropin-releasing hormone (GnRH) antagonists are used to prevent patients from releasing the eggs too early i.e., before the time of the egg pickup procedure. The GnRH antagonist is routinely given on day five of ovarian stimulation treatment, or can be administered before or after day five. One particular clinical condition in which the use of GnRH antagonists has been reported to be beneficial is in patients with polycystic ovarian syndrome (PCOS), where a sex hormone imbalance leads to the growth of benign masses on the ovaries. In these patients the use of GnRH antagonists reduced the incidence of severe ovarian hyperstimulation syndrome (OHSS), where too many eggs develop in the ovaries, making them very large and painful. The aim of this study is to compare two treatment schedules used in women with PCOS during IVF. Both treatment schedules are used in routine clinical practice. However, the choice between the two is based on the judgment of the treating physician because there are no studies that have looked at whether one schedule is better than the other.

Who can participate?
Women aged 18-40 with PCOS undergoing ART

What does the study involve?
Participants are randomly allocated into one of two groups. One group receives GnRH antagonist
on day one, while the other group receives GnRH antagonist on day five of ovarian stimulation. The embryo implantation rate, pregnancy rate, delivery rate, miscarriage rate, and the incidence of severe OHSS are compared between the two groups.

What are the possible benefits and risks of participating?
There are no direct anticipated benefits from participating in the study. However, participation may help in the advancement of science by finding out which treatment schedule is superior to the other or to find out that the two schedules are similarly successful. There is no specific risk of participating in the study. Both schedules have been used in clinical practice with success. There are other potential risks and complications associated with the clinical practice of ovarian stimulation and IVF. Such risks include, but are not limited to, the risk of anaesthetic, bleeding, which may require further surgery to control, infection, multiple pregnancy, higher incidence of miscarriage and ectopic pregnancy, and higher incidence of congenital malformation (birth defects) and chromosomal (genetic) abnormalities in babies born as a result of IVF. There is also a possible link between the use of fertility medication and ovarian cancer. Patients who use fertility medications are at increased risk of a condition called severe hyperstimulation syndrome, which could result in serious complications such as blood clot formation, kidney failure, fluid in the peritoneal cavity and around the lungs, and ovarian twisting, which would require surgery to correct.

Where is the study run from?
Hurley Medical Center (USA)

When is the study starting and how long is it expected to run for?
January 2006 to December 2009

Who is funding the study?
IVF Michigan, P.C. (USA)

Who is the main contact?
Dr Mostafa Abuzeid
reprod1@hurleymc.com

Contact information

Dr Mostafa Abuzeid
Scientific

Two Hurley Plaza
Suite 209
Flint
48503
United States of America

Phone + 1 810 262 9714
Email reprod1@hurleymc.com

Study information

Study designSingle-center physician-blinded prospective randomized trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleControlled ovarian hyperstimulation with long versus conventional protocol of gonadotropin-releasing hormone (GnRH) antagonist in women with polycystic ovarian disease (PCOD) undergoing assisted reproduction: a randomized controlled trial
Study objectivesThe purpose of this study was to test the hypothesis that in women with polycystic ovarian syndrome (PCOS), early initiation of GnRH-ant. (day 1 of ovarian stimulation) is associated with higher implantation rate compared to conventional GnRH-antagonist protocol (starting on day 5 of ovarian stimulation).
Ethics approval(s)Institutional Review Board at Hurley Medical Center, 31/10/2006, ref: 195632-1
Health condition(s) or problem(s) studiedPolycystic ovarian syndrome
InterventionControlled ovarian stimulation (COS) for intracytoplasmic sperm aspiration (ICSI) procedures in infertile patients with polycystic ovarian syndrome (PCOS). Two groups were studied.

The study group (group 1) received GnRH- antagonist subcutaneously (SC) starting on the same day on the beginning of COS using SC recombinant follicle stimulating hormone(r-FSH) 150-225 IU daily.

The control group (group 2) received GnRH- antagonist SC starting on treatment day 5 of SC r-FSH (150 -225 IU daily).

The implantation rate, clinical pregnancy rate, delivery rate, miscarriage rate, and the incidence of severe ovarian hyperstimulation syndrome between the two groups were compared.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Recombinant follicle stimulating hormone
Primary outcome measureImplantation rates evaluated at the end of the study
Secondary outcome measures1. Clinical pregnancy, delivery, and miscarriage rates
2. The incidence of severe ovarian hyperstimulation syndrome (OHSS)
Overall study start date01/01/2006
Completion date30/12/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit40 Years
SexFemale
Target number of participants140
Key inclusion criteria1. Women (age between 18-40 years) with PCOS, undergoing assisted reproductive technology (ART). PCOS was defined according to Rotterdam criteria at least 2 of the following 3 features:
1.1. Oligo and/or anovulation
1.2. Clinical and/or biochemical signs of hyperandrogenism and
1.3. Polycystic ovary on ultrasound scan (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group 2004)
Key exclusion criteria1. Hypothyroidism
2. Hyperprolactinemia
3. Non-classical form of congenital adrenal hyperplasia
4. Cushing’s syndrome
5. Androgen-secreting tumors
Date of first enrolment01/01/2006
Date of final enrolment30/12/2009

Locations

Countries of recruitment

  • United States of America

Study participating centre

Hurley Medical Center
Flint
48503
United States of America

Sponsor information

Hurley Medical Center (USA)
Hospital/treatment centre

Two Hurley Plaza
Suite 209
Flint
48503
United States of America

Phone + 1 810 262 9714
Email reprod1@hurleymc.com
ROR logo "ROR" https://ror.org/034npj057

Funders

Funder type

Hospital/treatment centre

IVF Michigan, P.C. (USA)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

14/02/2017: Plain English summary added.